A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza, Fernando C; Canetta, Pietro A; Barbour, Sean J; Lafayette, Richard A; Rovin, Brad H; Aslam, Nabeel; Hladunewich, Michelle A; Irazabal, Maria V; Sethi, Sanjeev; Gipson, Debbie S; Reich, Heather N; Brenchley, Paul; Kretzler, Matthias; Radhakrishnan, Jai; Hebert, Lee A; Gipson, Patrick E; Thomas, Leslie F; McCarthy, Ellen T; Appel, Gerald B; Jefferson, J Ashley; Eirin, Alfonso; Lieske, John C; Hogan, Marie C; Greene, Eddie L; Dillon, John J; Leung, Nelson; Sedor, John R; Rizk, Dana V; Blumenthal, Samuel S; Lasic, Lada B; Juncos, Luis A; Green, Dollie F; Simon, James; Sussman, Amy N; Philibert, David; Cattran, Daniel C.
; 130(3): 159-68, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26087670
Rituximab or Cyclosporine in the Treatment of Membranous Nephropathy.
A First Step toward a New Approach to Treating Membranous Nephropathy.
Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
Cyclosporine A for severe atopic dermatitis in children. efficacy and safety in a retrospective study of 63 patients.
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study.
Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab.
Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome.
A clinical audit of high-cost and off-label drug use in dermatology.
Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis.